table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 hospitalized
cilgavimab and tixagevimab (Evusheld) ACTIV-3/TICO ...

2 studies excluded by filtering options 1

9866 Jurdi, 2022 1110not a RCTrisk of bias not avaialble
10191 Chen, 2022 0100selection pending

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons